Neurotrope, Inc. (NTRP)

Trade NTRP now with
1/22/2020 9:07:41 AM Neurotrope Continues To Review Several Viable Strategic Alternatives
9/9/2019 8:37:19 AM Neurotrope: Phase 2 Study Of Bryostatin-1 Did Not Achieve Statistical Significance On Primary Endpoint
8/13/2019 8:31:37 AM Neurotrope Announces Publication Highlighting Potential Of Bryostatin As A Unique Neurorestorative Therapy
7/15/2019 8:35:13 AM Neurotrope Concludes Data Collection In Confirmatory Phase 2 Clinical Trial Of Bryostatin-1
3/21/2019 10:00:57 AM Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease
3/13/2019 8:34:17 AM Akari Therapeutics Says Positive FDA Meeting Outlines Path Ahead For Coversin In HSCT-TMA
3/13/2019 8:31:48 AM Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study Of Bryostatin-1 In Moderate To Severe Alzheimer's Disease
12/17/2018 9:15:28 AM Neurotrope Reports Publication Of Phase 2 Study Of Bryostatin-1 In The Journal Of Alzheimer's Disease
12/17/2018 9:05:14 AM Neurotrope Appoints Two New Members To Its Board, Ivan Gergel And Jonathan Schechter
9/26/2018 8:32:58 AM Neurotrope To Present Addl Phase 2 Data At 11th Edition Of Clinical Trials On Alzheimer's Disease (CTAD2018)
5/7/2018 8:37:22 AM Neurotrope Completes Study Design For Confirmatory Phase 2 Trial In Advanced Alzheimer's Patients
1/5/2018 9:31:24 AM Neurotrope' Bryostatin Improves Cognition In Patients With Advanced Alzheimer's Disease On Analysis Of Phase 2 Trial